Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Arrhythmias

  Free Subscription


Articles published in Am Heart J

Retrieve available abstracts of 69 articles:
HTML format
Text format



Single Articles


    September 2018
  1. REIMOLD FR, Reynolds MR
    Proarrhythmia and death with antiarrhythmic drugs for atrial fibrillation, and the unfulfilled promise of comparative effectiveness research.
    Am Heart J. 2018 Sep 12. pii: S0002-8703(18)30254.
    PubMed     Text format    


    August 2018
  2. VAN MIEGHEM NM, Unverdorben M, Valgimigli M, Mehran R, et al
    EdoxabaN Versus standard of care and theIr effectS on clinical outcomes in pAtients havinG undergonE Transcatheter Aortic Valve Implantation in Atrial Fibrillation-Rationale and design of the ENVISAGE-TAVI AF trial.
    Am Heart J. 2018;205:63-69.
    PubMed     Text format     Abstract available


  3. FRIBERG L
    Ventricular arrhythmia and death among atrial fibrillation patients using anti-arrhythmic drugs.
    Am Heart J. 2018;205:118-127.
    PubMed     Text format     Abstract available


  4. LI L, Selvin E, Lutsey PL, Hoogeveen RC, et al
    Association of N-terminal pro B-type natriuretic peptide (NT-proBNP) change with the risk of atrial fibrillation in the ARIC cohort.
    Am Heart J. 2018;204:119-127.
    PubMed     Text format     Abstract available


  5. DINOV B, Oebel S, Hilbert S, Loebe S, et al
    Characteristics of the ablation lesions in cardiac magnetic resonance imaging after radiofrequency ablation of ventricular arrhythmias in relation to the procedural success.
    Am Heart J. 2018;204:68-75.
    PubMed     Text format     Abstract available


    July 2018
  6. PICCINI JP, Calkins H
    Catheter ablation of rotational activity in atrial fibrillation: A barren oasis?
    Am Heart J. 2018 Jul 31. pii: S0002-8703(18)30229.
    PubMed     Text format    


  7. GUNDLUND A, Kumler T, Olesen JB, Bonde AN, et al
    Comparative thromboembolic risk in atrial fibrillation patients with and without a concurrent infection.
    Am Heart J. 2018;204:43-51.
    PubMed     Text format     Abstract available


  8. BALDERSTON JR, Gertz ZM, Ellenbogen KA, Schaaf KP, et al
    Association between ventricular fibrillation amplitude immediately prior to defibrillation and defibrillation success in out-of-hospital cardiac arrest.
    Am Heart J. 2018;201:72-76.
    PubMed     Text format     Abstract available


  9. PASSMAN R
    Atrial fibrillation and stroke: The more we learn, the less we understand.
    Am Heart J. 2018;201:158-159.
    PubMed     Text format    


    June 2018
  10. CHI G, Kerneis M, Kalayci A, Liu Y, et al
    Safety and efficacy of non-vitamin K oral anticoagulant for atrial fibrillation patients after percutaneous coronary intervention: A bivariate analysis of the PIONEER AF-PCI and RE-DUAL PCI trial.
    Am Heart J. 2018;203:17-24.
    PubMed     Text format     Abstract available


  11. ATZEMA CL, Dorian P, Fang J, Tu JV, et al
    A clinical decision instrument to predict 30-day death and cardiovascular hospitalizations after an emergency department visit for atrial fibrillation: The Atrial Fibrillation in the Emergency Room, Part 2 (AFTER2) study.
    Am Heart J. 2018;203:85-92.
    PubMed     Text format     Abstract available


  12. PASTORI D, Pignatelli P, Cribari F, Carnevale R, et al
    Time to therapeutic range (TtTR), anticoagulation control, and cardiovascular events in vitamin K antagonists-naive patients with atrial fibrillation.
    Am Heart J. 2018;200:32-36.
    PubMed     Text format     Abstract available


  13. LUBITZ SA, Khurshid S, Weng LC, Doros G, et al
    Predictors of oral anticoagulant non-prescription in patients with atrial fibrillation and elevated stroke risk.
    Am Heart J. 2018;200:24-31.
    PubMed     Text format     Abstract available


  14. LOPES RD, Vora AN, Liaw D, Granger CB, et al
    An open-Label, 2 x 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention:
    Am Heart J. 2018;200:17-23.
    PubMed     Text format     Abstract available


  15. CHEN ST, Hellkamp AS, Becker RC, Berkowitz SD, et al
    Impact of polyvascular disease on patients with atrial fibrillation: Insights from ROCKET AF.
    Am Heart J. 2018;200:102-109.
    PubMed     Text format     Abstract available


    May 2018
  16. PICCINI JP, Connolly SJ, Abraham WT, Healey JS, et al
    A genotype-directed comparative effectiveness trial of Bucindolol and metoprolol succinate for prevention of symptomatic atrial fibrillation/atrial flutter in patients with heart failure: Rationale and design of the GENETIC-AF trial.
    Am Heart J. 2018;199:51-58.
    PubMed     Text format     Abstract available


  17. PACKER DL, Mark DB, Robb RA, Monahan KH, et al
    Catheter Ablation versus Antiarrhythmic Drug Therapy for Atrial Fibrillation (CABANA) Trial: Study Rationale and Design.
    Am Heart J. 2018;199:192-199.
    PubMed     Text format     Abstract available


  18. YAO X, Gersh BJ, Sangaralingham LR, Shah ND, et al
    Risk of cardiovascular events and incident atrial fibrillation in patients without prior atrial fibrillation: Implications for expanding the indications for anticoagulation.
    Am Heart J. 2018;199:137-143.
    PubMed     Text format     Abstract available


  19. ECKMAN MH, Costea A, Attari M, Munjal J, et al
    Shared decision-making tool for thromboprophylaxis in atrial fibrillation - A feasibility study.
    Am Heart J. 2018;199:13-21.
    PubMed     Text format     Abstract available


  20. KIM D, Yang PS, Jang E, Yu HT, et al
    10-year nationwide trends of the incidence, prevalence, and adverse outcomes of non-valvular atrial fibrillation nationwide health insurance data covering the entire Korean population.
    Am Heart J. 2018;202:20-26.
    PubMed     Text format     Abstract available


    April 2018
  21. PERERA KS, Sharma M, Connolly SJ, Wang J, et al
    Stroke type and severity in patients with subclinical atrial fibrillation: An analysis from the Asymptomatic Atrial Fibrillation and Stroke Evaluation in Pacemaker Patients and the Atrial Fibrillation Reduction Atrial Pacing Trial (ASSERT).
    Am Heart J. 2018 Apr 18. pii: S0002-8703(18)30120.
    PubMed     Text format     Abstract available


  22. COX JL, Parkash R, Abidi SS, Thabane L, et al
    Optimizing primary care management of atrial fibrillation: The rationale and methods of the Integrated Management Program Advancing Community Treatment of Atrial Fibrillation (IMPACT-AF) study.
    Am Heart J. 2018;201:149-157.
    PubMed     Text format     Abstract available


  23. HUISMAN MV, Rothman KJ, Paquette M, Teutsch C, et al
    Two-year follow-up of patients treated with dabigatran for stroke prevention in atrial fibrillation: Global Registry on Long-Term Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) registry.
    Am Heart J. 2018;198:55-63.
    PubMed     Text format     Abstract available


  24. FAUCHIER L, Bisson A, Clementy N, Vourc'h P, et al
    Changes in glomerular filtration rate and outcomes in patients with atrial fibrillation.
    Am Heart J. 2018;198:39-45.
    PubMed     Text format     Abstract available


  25. HIJAZI Z, Hohnloser SH, Oldgren J, Andersson U, et al
    Efficacy and safety of dabigatran compared with warfarin in patients with atrial fibrillation in relation to renal function over time-A RE-LY trial analysis.
    Am Heart J. 2018;198:169-177.
    PubMed     Text format    


  26. MIYAZAWA K, Pastori D, Lip GYH
    Changes in renal function in patients with atrial fibrillation: Efficacy and safety of the non-vitamin K antagonist oral anticoagulants.
    Am Heart J. 2018;198:166-168.
    PubMed     Text format    


    March 2018
  27. GARG PK, Bartz TM, Norby FL, Jorgensen NW, et al
    Association of lipoprotein-associated phospholipase A2 and risk of incident atrial fibrillation: Findings from 3 cohorts.
    Am Heart J. 2018;197:62-69.
    PubMed     Text format     Abstract available


  28. KOPIN D, Jones WS, Sherwood MW, Wojdyla DM, et al
    Percutaneous coronary intervention and antiplatelet therapy in patients with atrial fibrillation receiving apixaban or warfarin: Insights from the ARISTOTLE trial.
    Am Heart J. 2018;197:133-141.
    PubMed     Text format     Abstract available


  29. VERMA A, Ha ACT, Kirchhof P, Hindricks G, et al
    The Optimal Anti-Coagulation for Enhanced-Risk Patients Post-Catheter Ablation for Atrial Fibrillation (OCEAN) trial.
    Am Heart J. 2018;197:124-132.
    PubMed     Text format     Abstract available


    February 2018
  30. VRANCKX P, Lewalter T, Valgimigli M, Tijssen JG, et al
    Evaluation of the safety and efficacy of an edoxaban-based antithrombotic regimen in patients with atrial fibrillation following successful percutaneous coronary intervention (PCI) with stent placement: Rationale and design of the ENTRUST-AF PCI trial
    Am Heart J. 2018;196:105-112.
    PubMed     Text format     Abstract available


    January 2018
  31. LARSSON SC, Drca N, Jensen-Urstad M, Wolk A, et al
    Chocolate consumption and risk of atrial fibrillation: Two cohort studies and a meta-analysis.
    Am Heart J. 2018;195:86-90.
    PubMed     Text format     Abstract available


  32. YONG CM, Liu Y, Apruzzese P, Doros G, et al
    Association of insurance type with receipt of oral anticoagulation in insured patients with atrial fibrillation: A report from the American College of Cardiology NCDR PINNACLE registry.
    Am Heart J. 2018;195:50-59.
    PubMed     Text format     Abstract available


  33. CLARK NP, Douketis JD, Hasselblad V, Schulman S, et al
    Predictors of perioperative major bleeding in patients who interrupt warfarin for an elective surgery or procedure: Analysis of the BRIDGE trial.
    Am Heart J. 2018;195:108-114.
    PubMed     Text format     Abstract available


    December 2017
  34. OKUMURA K, Lip GYH, Akao M, Tanizawa K, et al
    Edoxaban for the management of elderly Japanese patients with atrial fibrillation ineligible for standard oral anticoagulant therapies: Rationale and design of the ELDERCARE-AF study.
    Am Heart J. 2017;194:99-106.
    PubMed     Text format     Abstract available


  35. ECKMAN MH, Costea A, Attari M, Munjal J, et al
    Atrial fibrillation decision support tool: Population perspective.
    Am Heart J. 2017;194:49-60.
    PubMed     Text format     Abstract available


  36. STEINBERG BA, Gao H, Shrader P, Pieper K, et al
    International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: Results from the GARFIELD-AF, ORBIT-AF I, and ORBIT-AF II registries.
    Am Heart J. 2017;194:132-140.
    PubMed     Text format     Abstract available


    November 2017
  37. LIP GYH, Al-Saady N, Ezekowitz MD, Banach M, et al
    The relationship of renal function to outcome: A post hoc analysis from the EdoxabaN versus warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE-AF) study.
    Am Heart J. 2017;193:16-22.
    PubMed     Text format     Abstract available


  38. DA COSTA A, Delolme C, Guichard JB, Gerbay A, et al
    Comparison of prevalence and management of left atrial appendage thrombi under old and new anticoagulants prior to left atrial catheter ablation.
    Am Heart J. 2017;193:8-15.
    PubMed     Text format     Abstract available


    October 2017
  39. MOJOLI M, Gersh BJ, Barioli A, Masiero G, et al
    Impact of atrial fibrillation on outcomes of patients treated by transcatheter aortic valve implantation: A systematic review and meta-analysis.
    Am Heart J. 2017;192:64-75.
    PubMed     Text format     Abstract available


  40. KESSLER M, Gonska B, Seeger J, Rottbauer W, et al
    Predictors of permanent pacemaker implantation after transfemoral aortic valve implantation with the Lotus valve.
    Am Heart J. 2017;192:57-63.
    PubMed     Text format     Abstract available


  41. VINEREANU D, Al-Khalidi HR, Rao MP, He W, et al
    Regional differences in presentation and antithrombotic treatment of patients with atrial fibrillation: Baseline characteristics from a clustered randomized trial to IMProve treatment with AntiCoagulanTs in patients with atrial fibrillation (IMPACT-AF
    Am Heart J. 2017;192:38-47.
    PubMed     Text format     Abstract available


  42. FASHANU OE, Norby FL, Aguilar D, Ballantyne CM, et al
    Galectin-3 and incidence of atrial fibrillation: The Atherosclerosis Risk in Communities (ARIC) study.
    Am Heart J. 2017;192:19-25.
    PubMed     Text format     Abstract available


    September 2017
  43. FRIEDMAN DJ, Al-Khatib SM, Zeitler EP, Han J, et al
    New York Heart Association class and the survival benefit from primary prevention implantable cardioverter defibrillators: A pooled analysis of 4 randomized controlled trials.
    Am Heart J. 2017;191:21-29.
    PubMed     Text format     Abstract available


  44. O'NEILL ES, Grande SW, Sherman A, Elwyn G, et al
    Availability of patient decision aids for stroke prevention in atrial fibrillation: A systematic review.
    Am Heart J. 2017;191:1-11.
    PubMed     Text format     Abstract available


    August 2017
  45. HIJAZI Z, Oldgren J, Andersson U, Connolly SJ, et al
    Growth-differentiation factor 15 and risk of major bleeding in atrial fibrillation: Insights from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial.
    Am Heart J. 2017;190:94-103.
    PubMed     Text format     Abstract available


  46. PROIETTI M, Airaksinen KEJ, Rubboli A, Schlitt A, et al
    Time in therapeutic range and major adverse outcomes in atrial fibrillation patients undergoing percutaneous coronary intervention: The Atrial Fibrillation Undergoing Coronary Artery Stenting (AFCAS) registry.
    Am Heart J. 2017;190:86-93.
    PubMed     Text format     Abstract available


  47. BERNSTEIN RA, Kamel H, Granger CB, Kowal RC, et al
    Stroke of Known Cause and Underlying Atrial Fibrillation (STROKE-AF) randomized trial: Design and rationale.
    Am Heart J. 2017;190:19-24.
    PubMed     Text format     Abstract available


  48. KIRCHHOF P, Blank BF, Calvert M, Camm AJ, et al
    Probing oral anticoagulation in patients with atrial high rate episodes: Rationale and design of the Non-vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes (NOAH-AFNET 6) trial.
    Am Heart J. 2017;190:12-18.
    PubMed     Text format     Abstract available


    July 2017
  49. PERINI AP, Kutyifa V, Veazie P, Daubert JP, et al
    Effects of implantable cardioverter/defibrillator shock and antitachycardia pacing on anxiety and quality of life: A MADIT-RIT substudy.
    Am Heart J. 2017;189:75-84.
    PubMed     Text format     Abstract available


  50. STEINBERG BA, Shrader P, Thomas L, Ansell J, et al
    Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II).
    Am Heart J. 2017;189:40-47.
    PubMed     Text format     Abstract available


  51. KUTYIFA V, Beck C, Brown MW, Cannom D, et al
    Multicenter Automatic Defibrillator Implantation Trial-Subcutaneous Implantable Cardioverter Defibrillator (MADIT S-ICD): Design and clinical protocol.
    Am Heart J. 2017;189:158-166.
    PubMed     Text format     Abstract available


  52. LOPES RD, Alings M, Connolly SJ, Beresh H, et al
    Rationale and design of the Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA) trial.
    Am Heart J. 2017;189:137-145.
    PubMed     Text format     Abstract available


  53. HOLMES DR, Reddy VY, Buchbinder M, Stein K, et al
    The Assessment of the Watchman Device in Patients Unsuitable for Oral Anticoagulation (ASAP-TOO) trial.
    Am Heart J. 2017;189:68-74.
    PubMed     Text format     Abstract available


    June 2017
  54. GRAVES KG, May HT, Jacobs V, Bair TL, et al
    Atrial fibrillation incrementally increases dementia risk across all CHADS2 and CHA2DS2VASc strata in patients receiving long-term warfarin.
    Am Heart J. 2017;188:93-98.
    PubMed     Text format     Abstract available


  55. GRAFF S, Prior A, Fenger-Gron M, Christensen B, et al
    Does perceived stress increase the risk of atrial fibrillation? A population-based cohort study in Denmark.
    Am Heart J. 2017;188:26-34.
    PubMed     Text format     Abstract available


    May 2017
  56. GEHI AK, Doros G, Glorioso TJ, Grunwald GK, et al
    Factors associated with rhythm control treatment decisions in patients with atrial fibrillation-Insights from the NCDR PINNACLE registry.
    Am Heart J. 2017;187:88-97.
    PubMed     Text format     Abstract available


  57. KARLSSON LO, Nilsson S, Charitakis E, Bang M, et al
    Clinical decision support for stroke prevention in atrial fibrillation (CDS-AF): Rationale and design of a cluster randomized trial in the primary care setting.
    Am Heart J. 2017;187:45-52.
    PubMed     Text format     Abstract available


  58. DIEDERICHSEN SZ, Haugan KJ, Kober L, Hojberg S, et al
    Atrial fibrillation detected by continuous electrocardiographic monitoring using implantable loop recorder to prevent stroke in individuals at risk (the LOOP study): Rationale and design of a large randomized controlled trial.
    Am Heart J. 2017;187:122-132.
    PubMed     Text format     Abstract available


  59. PICCINI JP, Clark RL, Kowey PR, Mittal S, et al
    Long-term electrocardiographic safety monitoring in clinical drug development: A report from the Cardiac Safety Research Consortium.
    Am Heart J. 2017;187:156-169.
    PubMed     Text format     Abstract available


    April 2017
  60. EGBE AC, Connolly HM, Khan AR, Niaz T, et al
    Outcomes in adult Fontan patients with atrial tachyarrhythmias.
    Am Heart J. 2017;186:12-20.
    PubMed     Text format     Abstract available


  61. WAN C, Szymkiewicz SJ, Klein HU
    The impact of body mass index on the wearable cardioverter defibrillator shock efficacy and patient wear time.
    Am Heart J. 2017;186:111-117.
    PubMed     Text format     Abstract available


    March 2017
  62. SMITH WM, Riddell F, Madon M, Gleva MJ, et al
    Comparison of diagnostic value using a small, single channel, P-wave centric sternal ECG monitoring patch with a standard 3-lead Holter system over 24 hours.
    Am Heart J. 2017;185:67-73.
    PubMed     Text format     Abstract available


  63. KUPSKY DF, Ahmed AM, Sakr S, Qureshi WT, et al
    Cardiorespiratory fitness and incident heart failure: The Henry Ford ExercIse Testing (FIT) Project.
    Am Heart J. 2017;185:35-42.
    PubMed     Text format     Abstract available


    February 2017
  64. FANOLA CL, Mooney D, Cowan AJ, Ko D, et al
    Incidence of severe renal dysfunction among individuals taking warfarin and implications for non-vitamin K oral anticoagulants.
    Am Heart J. 2017;184:150-155.
    PubMed     Text format     Abstract available


  65. SORENSEN LL, Liang HY, Pinheiro A, Hilser A, et al
    Safety profile and utility of treadmill exercise in patients with high-gradient hypertrophic cardiomyopathy.
    Am Heart J. 2017;184:47-54.
    PubMed     Text format     Abstract available


    January 2017
  66. EGBE AC, Connolly HM, Niaz T, Yogeswaran V, et al
    Prevalence and outcome of thrombotic and embolic complications in adults after Fontan operation.
    Am Heart J. 2017;183:10-17.
    PubMed     Text format     Abstract available


    September 2016
  67. GILOTRA NA, Bennett MK, Shpigel A, Ahmed HM, et al
    Outcomes and predictors of recovery in acute-onset cardiomyopathy: A single-center experience of patients undergoing endomyocardial biopsy for new heart failure.
    Am Heart J. 2016;179:116-26.
    PubMed     Text format     Abstract available


    August 2016
  68. O'DONNELL MJ, Eikelboom JW, Yusuf S, Diener HC, et al
    Effect of apixaban on brain infarction and microbleeds: AVERROES-MRI assessment study.
    Am Heart J. 2016;178:145-50.
    PubMed     Text format     Abstract available


    July 2016
  69. TING R, Tejpal A, Finken L, Fisher M, et al
    Repatriation to referral hospital after reperfusion of STEMI patients transferred for primary percutaneous coronary intervention: Insights of a Canadian regional STEMI care system.
    Am Heart J. 2016;177:145-52.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Arrhythmias is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: